BioLineRx (BLRX) Stock Price, News & Analysis

Company Overview

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for oncology, immunology and neuroscience indications. The company’s pipeline includes small molecules and peptides designed to address areas of high unmet medical need, with a primary emphasis on the treatment of various cancers and immune-related disorders. BioLineRx pursues a rigorous, science-driven approach, advancing candidates from preclinical research through Phase II and III clinical trials.

Among its lead programs is motixafortide (BL-8040), a selective CXCR4 antagonist being evaluated in combination regimens for acute myeloid leukemia and metastatic pancreatic cancer. Additional pipeline assets include BL-1020, a GABA-modulating agent for the treatment of schizophrenia, and other proprietary candidates targeting fibrosis, neuroinflammation and acute pain. These programs leverage targeted mechanisms of action to achieve improved efficacy and safety profiles compared with existing therapies.

Founded in 2003 and headquartered in Petah Tikva, Israel, BioLineRx has established collaborations with leading academic institutions and contract research organizations across North America, Europe and Asia. The company’s global footprint supports multi-center clinical trials, regulatory filings and strategic partnerships aimed at accelerating the development of its pipeline. Through licensing agreements and co-development arrangements, BioLineRx seeks to maximize the commercial potential of its candidates while managing development risk.

BioLineRx is guided by an experienced management team and board of directors with deep expertise in biotechnology, clinical development and corporate finance. The leadership team combines academic research credentials with industry experience, fostering a disciplined approach to program prioritization, regulatory strategy and investor relations. With a commitment to scientific excellence and patient-centric innovation, BioLineRx strives to bring new treatment options to market for challenging diseases.

Key Stats

• Today's Range: $4.63 to $4.91
• 50-Day Range: $3.09 to $5.93
• 52-Week Range: $2.30 to $35.60
• Volume: 41,348 shs
• Average Volume: 235,749 shs
• Market Capitalization: $20.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.00
• Consensus Rating: Strong Buy

BioLineRx Stock Analysis - MarketRank™

BioLineRx scored higher than 53% of companies evaluated by MarketBeat, and ranked 552nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

BioLineRx has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BioLineRx has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioLineRx are expected to grow in the coming year, from ($5.80) to ($5.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioLineRx is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioLineRx is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioLineRx has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.46% of the float of BioLineRx has been sold short.

Short Interest Ratio / Days to Cover

BioLineRx has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioLineRx has recently decreased by 4.16%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioLineRx does not currently pay a dividend.

Dividend Growth

BioLineRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.46% of the float of BioLineRx has been sold short.

Short Interest Ratio / Days to Cover

BioLineRx has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioLineRx has recently decreased by 4.16%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.94

News Sentiment

BioLineRx has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for BioLineRx this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for BLRX on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioLineRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.10% of the stock of BioLineRx is held by insiders.

Percentage Held by Institutions

Only 1.56% of the stock of BioLineRx is held by institutions.

BLRX Stock Analysis - Frequently Asked Questions

How have BLRX shares performed this year?

BioLineRx's stock was trading at $8.56 at the beginning of the year. Since then, BLRX stock has decreased by 45.1% and is now trading at $4.70.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) posted its earnings results on Tuesday, May, 27th. The biotechnology company reported $1.39 EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $2.23. The biotechnology company had revenue of $11.75 million for the quarter, compared to the consensus estimate of $7.72 million. BioLineRx had a negative net margin of 15.21% and a negative trailing twelve-month return on equity of 23.93%.
Read the conference call transcript.

When did BioLineRx's stock split?

BioLineRx's stock reverse split before market open on Thursday, January 30th 2025.The 1-40 reverse split was announced on Friday, January 17th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioLineRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Savara (SVRA), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/27/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BLRX
• CIK: 1498403
• Web: www.biolinerx.com
• Phone: (728) 642-9100
• Fax: 972-8642-9101
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BioLineRx: $26.00
• High Price Target: $26.00
• Low Price Target: $26.00
• Potential Upside/Downside: +453.2%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.22 million
• Net Margins: -15.21%
• Pretax Margin: -15.21%
• Return on Equity: -23.93%
• Return on Assets: -6.80%

Debt

• Debt-to-Equity Ratio: 0.37
• Current Ratio: 2.27
• Quick Ratio: 2.04

Sales & Book Value

• Annual Sales: $28.94 million
• Price / Sales: 0.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.04 per share
• Price / Book: 1.16

Miscellaneous

• Outstanding Shares: 4,260,000
• Free Float: 4,216,000
• Market Cap: $20.02 million
• Optionable: Optionable
• Beta: 1.25